Biopharmaceutical News and Research

RSS

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2009.

11 Mar 2010

TTI granted exclusive worldwide rights to commercialize two immunology programs

Trillium Therapeutics Inc., a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into two definitive license agreements with University Health Network and The Hospital for Sick Children in Toronto, Ontario, granting Trillium exclusive worldwide rights to commercialize two immunology programs in the areas of hematopoietic stem cell transplantation and cancer.

11 Mar 2010

Veterans PTSD Project: Cannabis Science formalizes agreement with specialized FDA regulatory compliance firm

Cannabis Science, Inc., a pioneering pharmaceutical cannabis company, is pleased to announce that it has formalized its agreement with a privately owned, highly specialized international FDA regulatory compliance firm. The compliance firm will review and prepare technical data for Cannabis Science's FDA Pre-Investigative New Drug submission package for its Veterans PTSD Project.

11 Mar 2010

Celltrion develops novel human monoclonal antibodies against influenza virus infection

Celltrion, Inc., a South Korean biopharmaceutical company, has developed novel human monoclonal antibodies against influenza virus infection, which neutralize a broad spectrum of influenza viruses, including pandemic H1N1 and the deadly H5N1 avian influenza virus. Preliminary tests in laboratory animals indicate that the novel human monoclonal antibodies can be used to prevent disease when given either before or after infection.

10 Mar 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

Pharmaceutical Institute announces the release of Therapeutic Area Essentials

Pharmaceutical Institute, a leading provider of specialized training solutions for the pharmaceutical and biotech industry and a subsidiary of Campbell Alliance, today announced the release of Therapeutic Area Essentials™, a comprehensive suite of more than 155 therapeutic area e-courses covering diagnosis, cause, and treatment for over 40 disease states.

9 Mar 2010

Sartorius achieves operating earnings of 60.9M euros for 2009

Sartorius, a leading international laboratory and process equipment provider, increased its operating profit in 2009 despite the difficult macroeconomic climate and achieved operating earnings of 60.9 million euros, up from 56.8 million euros a year earlier. “As a result, we are among the companies that were able to close the 2009 year of crisis with a positive development of operating earnings,” commented CEO Dr. Joachim Kreuzburg on the company’s full-year results at the annual press conference in Goettingen, Germany.

From Sartorius 9 Mar 2010

BioSpecifics Technologies' XIAFLEX now available to Dupuytren's contracture patients in the U.S.

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX™ is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture patients with a palpable cord. Dupuytren's contracture is a debilitating disease resulting from excessive collagen deposition that causes contractures of the fingers.

8 Mar 2010

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Ricerca Biosciences, LLC, announced today the finalization of the acquisition of the Discovery and Preclinical business of MDS Pharma Services with facilities and almost 600 associates in Bothell, Washington; Lyon, France; and Taipei, Taiwan.

8 Mar 2010

Global Genes Project: World Rare Disease Day 2010, a tremendous success

The Global Genes Project, a worldwide rare disease awareness initiative, today announced the success from its World Rare Disease Day 2010 efforts and laid out plans for future rare disease awareness campaigns.

8 Mar 2010

Quintiles opens expanded research facility in London

Quintiles today announced the opening of its expanded research facility in London, UK, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.

8 Mar 2010

Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting

Acologix, Inc., a privately held biopharmaceutical company, today announced the results of its latest preclinical study demonstrating that AC-100, its therapeutic product candidate derived from an endogenous human protein, promotes cartilage regeneration in a large animal model. The data will be presented by Dr. David M. Rosen on March 6, 2010 at the 56th annual meeting of the ORS in New Orleans, LA.

8 Mar 2010

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.

6 Mar 2010

AMICAS and Merge Healthcare sign definitive merger agreement

AMICAS, Inc. and Merge Healthcare Incorporated (Nasdaq: MRGE) today announced that they will enter into a definitive merger agreement pursuant to which Merge will acquire all of the outstanding shares of AMICAS for $6.05 per share in cash, or an aggregate of $248 million.

5 Mar 2010

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

During a meeting with the investment community today, Bristol-Myers Squibb Company will provide a comprehensive business overview, highlight positive pipeline developments and provide 2013 minimum non-GAAP earnings per share guidance.

5 Mar 2010

Glencoe Enterprise article highlights medical innovation and research enable people to live longer, healthier

An article in the Glencoe Enterprise recently highlighted the fact that medical innovation and research are enabling many people to live longer, healthier and more productive lives.

5 Mar 2010

FDA's 5-year NCE exclusivity grant to VYVANSE: Court upholds decision

Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).

5 Mar 2010

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of $7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately $36.7 million.

5 Mar 2010

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).

4 Mar 2010

Biopharmaceutical News and Research

Advanced Life Sciences Holdings reports decrease in net loss for full-year 2009

TTI granted exclusive worldwide rights to commercialize two immunology programs

Veterans PTSD Project: Cannabis Science formalizes agreement with specialized FDA regulatory compliance firm

Celltrion develops novel human monoclonal antibodies against influenza virus infection

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Pharmaceutical Institute announces the release of Therapeutic Area Essentials

Sartorius achieves operating earnings of 60.9M euros for 2009

BioSpecifics Technologies' XIAFLEX now available to Dupuytren's contracture patients in the U.S.

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Global Genes Project: World Rare Disease Day 2010, a tremendous success

Quintiles opens expanded research facility in London

Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

AMICAS and Merge Healthcare sign definitive merger agreement

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Glencoe Enterprise article highlights medical innovation and research enable people to live longer, healthier

FDA's 5-year NCE exclusivity grant to VYVANSE: Court upholds decision

Anthera Pharmaceuticals completes initial public offering at $7.00 per share

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

Event guide: World ADC Asia eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News